Antioxidant defense system in prostate adenocarcinoma and benign prostate hyperplasia of elderly patients

Szewczyk-Golec, Karolina; Tyloch, Janusz; Czuczejko, Jolanta

doi:10.4149/neo_2015_015

Cited by 12 publications

(12 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar insignificant SOD changes in BPH patients have been reported by others. 18 On the contrary, a study conducted to investigate the oxidative stress indicators in patients with prostate disorders reported significant lower GSH-Px and SOD levels in patients. 19 The role of antioxidants in BPH development does not appear to be clear due to conflicting observations from other studies.…”

Section: Discussionmentioning

confidence: 98%

Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients

Asare

Andam

Asare‐Anane

et al. 2018

Prostate International

View full text Add to dashboard Cite

BackgroundOxidative stress and antioxidants have been implicated in many diseases including prostate cancer and benign prostatic hyperplasia (BPH). Lipid peroxidation contributes to oxidative stress. However, new and emerging antioxidants such as paraoxonase 1 (PON1) and arylesterase (ARE) associated with lipoprotein peroxidation have not been examined in BPH patients. PON1 and ARE, a high-density lipoprotein (HDL) cholesterol-bound enzyme system of antioxidants, protect low-density lipoprotein (LDL) cholesterol and HDL from oxidation by hydrolysis. The study primarily determined paraoxonase (PON1) and ARE activities in BPH treatment-naïve patients.Materials and methodsSixty newly diagnosed patients (treatment-naïve) alongside 30 apparently healthy controls were recruited. Blood examinations included lipid profile (total cholesterol, triglycerides, LDL, HDL), glutathione peroxidase, PON1, ARE, and prostate specific antigen (PSA).Prostate volume and International Prostate Symptoms Score (IPSS) were determined.ResultsPSA was significantly different between patient and control groups (P < 0.0001). Total cholesterol, triglycerides, and LDL were significantly higher in the patient group (P = 0.002, P < 0.001, P = 0.003, respectively). Glutathione peroxidase was very low in the patient group compared to the control group (5.65 ± 2.30 ng/mL and 17.43 ± 10.98 ng/mL, respectively). Although PON1 was higher in the patient group (50.22 ± 19.68/61.30 ± 29.55 ng/mL; P > 0.05), ARE was significantly lower in the patient group (61.31 ± 21.76/49.30 ± 19.82 ng/mL; P = 0.0098). No correlation was established between antioxidants and the lipid profile except for the LDL and PON1 patient group (r = 0.1486, P = 0.0374). Similarly, a weak correlation was also established between PSA and LDL in the patient group (r = –0.275, P = 0.033). PON1/HDL ratio was not significantly different. However, the ARE/HDL ratio was significantly lower in the patient group (P < 0.0001).ConclusionThese results signify the presence of a higher lipoprotein peroxidation activity and lower lipid-associated antioxidant activity in the patient group. The ARE/HDL ratio is a better indicator of the HDL associated antioxidant than the PON1/HDL ratio or the individual antioxidants (PON1 and ARE) as reported by others.

show abstract

Section: Discussionmentioning

confidence: 98%

Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients

Asare

Andam

Asare‐Anane

et al. 2018

Prostate International

View full text Add to dashboard Cite

show abstract

“…Researchers have suggested that oxidative stress can have an impact on the pathophysiology of BPH. For instance, the weakness of the antioxidant defense system has been found to be concurrent with the BPH progress in elderly patients (Szewczyk‐Golec, Tyloch, & Czuczejko, ). The activities of antioxidant enzymes decrease significantly in prostatic hyperplasia.…”

Section: Introductionmentioning

confidence: 99%

Changes in the oxidative stress factors and inflammatory proteins following the treatment of BPH‐induced dogs with an anti‐proliferative agent called tadalafil

Dearakhshandeh

Mogheiseh

Nazifi

et al. 2019

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Background Finding a medical treatment which can combat cell proliferation and relax smooth muscles in canine benign prostatic hyperplasia (BPH) appears to be imperative. Aims This study aimed to evaluate the oxidative stress and inflammatory proteins following the treatment of dogs induced for BPH with an anti‐proliferative agent called tadalafil. Materials and Methods Twenty‐five adult intact male dogs were randomly designated into five groups (n = 5): Control group was not induced for BPH and not treated with tadalafil; dogs induced for BPH by testosterone enanthate and estradiol benzoate and treated with tadalafil (5 mg/day P.O.); dogs which received tadalafil (5 mg/day P.O.); dogs induced for BPH and treated with castration; and dogs induced for BPH. Oxidative stress factors (glutathione peroxidase [GPX], superoxide dismutase [SOD], catalase) and inflammatory proteins (haptoglobin, serum amyloid A [SAA], malondialdehyde [MDA]) were measured in the blood serum for four sequential weeks. Results Glutathione peroxidase and SOD serum levels declined in dogs in the BPH‐induced group compared to those in the control group. Those levels diminished in BPH‐induced castrated and tadalafil‐treated groups. The changes in the GPX and SOD serum concentrations were not significant between the BPH‐induced castrated group and BPH‐induced tadalafil‐treated group. Moreover, MDA concentration increased slightly in groups with BPH and groups which were castrated. Generally, however, there were no significant differences in the MDA serum concentrations between other groups. Haptoglobin and SAA concentrations increased in BPH‐castrated group. Also, the differences in haptoglobin and SAA were not significant between the groups. Conclusion Tadalafil could not control oxidative stress and inflammatory mediators which happened during BPH in dogs.

show abstract

“…Oxidative stress influences the pathophysiology of both PCa and BPH. For instance, antioxidant defense system is decreased in the elderly patients with PCa and BPH [ 66 ]. Also, systemic metabolic stress occurs in glucose and fatty acid metabolism in BPH and PCa [ 67 ].…”

Section: Introductionmentioning

confidence: 99%

“…On the other hand, according to the free radical theory of aging, oxidative stress is blamed for aging because of the negative impact the excessive free radicals or reactive oxygen species (ROS) have on the cells [ 71 ]. Also, antioxidant defense system is decreased in the elderly patients with PCa [ 66 ]. ROS and age are predominant factors in PCa and other aging-related diseases, such as, diabetes, atherosclerosis and degenerative diseases like Parkinson’s and Alzheimer’s.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oxidative stress in prostate hyperplasia and carcinogenesis

Udensi

Tchounwou

2016

J Exp Clin Cancer Res

123

View full text Add to dashboard Cite

Prostatic hyperplasia (PH) is a common urologic disease that affects mostly elderly men. PH can be classified as benign prostatic hyperplasia (BPH), or prostate cancer (PCa) based on its severity. Oxidative stress (OS) is known to influence the activities of inflammatory mediators and other cellular processes involved in the initiation, promotion and progression of human neoplasms including prostate cancer. Scientific evidence also suggests that micronutrient supplementation may restore the antioxidant status and hence improve the clinical outcomes for patients with BPH and PCa. This review highlights the recent studies on prostate hyperplasia and carcinogenesis, and examines the role of OS on the molecular pathology of prostate cancer progression and treatment.

show abstract

Antioxidant defense system in prostate adenocarcinoma and benign prostate hyperplasia of elderly patients

Cited by 12 publications

References 33 publications

Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients

Lipid associated antioxidants: arylesterase and paraoxonase-1 in benign prostatic hyperplasia treatment-naïve patients

Changes in the oxidative stress factors and inflammatory proteins following the treatment of BPH‐induced dogs with an anti‐proliferative agent called tadalafil

Oxidative stress in prostate hyperplasia and carcinogenesis

Contact Info

Product

Resources

About